Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma-Reference-Cited by-同舟云学术

Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma

Published:2017-10-30 Issue:1 Volume:36 Page:110-115
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Klener Pavel¹²^ORCID,Fronkova Eva³,Belada David⁴,Forsterova Kristina¹,Pytlik Robert¹,Kalinova Marketa⁵,Simkovic Martin⁴,Salek David⁶,Mocikova Heidi⁷,Prochazka Vit⁸,Blahovcova Petra¹,Janikova Andrea⁶,Markova Jana⁷,Obr Ales⁸,Berkova Adela⁹,Kubinyi Jozef¹⁰,Vaskova Martina³,Mejstrikova Ester³,Campr Vit⁵,Jaksa Radek¹¹,Kodet Roman⁵,Michalova Kyra⁹,Trka Jan³,Trneny Marek¹

Affiliation:

1. First Medical Department; Charles University General Hospital in Prague; Prague Czech Republic

2. Institute of Pathological Physiology, First Faculty of Medicine; Charles University in Prague; Prague Czech Republic

3. CLIP, Deparment of Pediatric Hematology/Oncology; Second Faculty of Medicine and University Hospital in Motol; Prague Czech Republic

4. Fourth Department of Internal Medicine-Hematology; Charles University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove; Hradec Králové Czech Republic

5. Department of Pathology and Molecular Medicine; Charles University Hospital in Motol, Prague, and Second Faculty of Medicine; Prague Czech Republic

6. Department of Hematology and Oncology; Masaryk University Hospital in Brno; Brno Czech Republic

7. Department of Internal Medicine and Haematology; Faculty Hospital Kralovske Vinohrady and Third Faculty of Medicine, Charles University; Prague Czech Republic

8. Department of Hemato-Oncology; Faculty of Medicine and Dentistry, Palacky University and University Hospital Olomouc; Olomouc Czech Republic

9. Center of Oncocytogenetics, Institute of Clinical Biochemistry and Laboratory Diagnostics; First Faculty of Medicine, Charles University; Prague Czech Republic

10. Institute of Nuclear Medicine; Charles University General Hospital in Prague; Prague Czech Republic

11. Institute of Pathology; Charles University General Hospital Prague; Prague Czech Republic

Funder

Ministry of Education, Youth and Sports Institutional Support for Long-term Development of Research Organizations

Ministry of Health of the Czech Republic grant AZV

Research project awarded by Charles University, Third Faculty of Medicine, Prague, Czech Republic

Ministry of Education

Charles University Center of Excellence

Ministry of Health

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hon.2483/fullpdf

Reference10 articles.

1. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial;Rummel;Lancet,2013

2. Mantle cell lymphoma: 2015 update on diagnosis, risk-stratification, and clinical management;Vose;Am J Hematol,2015

3. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL younger): a randomised, open-label, phase 3 trial of the European mantle cell lymphoma network;Hermine;Lancet,2016

4. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic lymphoma group;Geisler;Blood,2008

5. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi;Visco;Lancet Haematol,2017

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sequencing‐based analysis of clonal evolution of 25 mantle cell lymphoma patients at diagnosis and after failure of standard immunochemotherapy;American Journal of Hematology;2023-08-21

2. Treatment of older patients with mantle cell lymphoma in the era of novel agents;Leukemia & Lymphoma;2023-06-26

3. Ibrutinib in mantle cell lymphoma: a real-world retrospective multi-center analysis of 77 patients treated in the Czech Republic;Annals of Hematology;2022-11-11

4. The Role of 18FDG-PET/CT in Malignant Lymphomas Clinical Implications;Artificial Intelligence in PET/CT Oncologic Imaging;2022

5. Association of minimal residual disease levels with clinical outcomes in patients with mantle cell lymphoma: A meta-analysis;Leukemia Research;2021-09